Solid dosage capsule form designed to be stable, dose flexible, patient-friendly, and commercially scalable, to be evaluated in a potential Phase 3 trial.
COVACTA trial did not meet primary endpoint of improved clinical status in patients with COVID-19 associated pneumonia, or the key secondary endpoints.